A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors
NCT00628732
Completed
The purposes of this study include: * Determination of the change in clearance of topotecan and topotecan lactone between day 1 and day 14 for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days. * Determination of the correlation between the activity of CYP3A4, as measured by the 14C- Erythromycin Breath Test (ERMBT), and topotecan/topotecan lactone clearance for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days. * Determinati... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/27/2009
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: Solid Tumors
Register for Updates
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
NCT00010413
Completed
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/01/2008
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Pemphigus
Register for Updates
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
NCT00578435
Completed
The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
09/10/2008
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Genetic Disorders, Sickle Cell Anemia
Register for Updates
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
NCT00010387
Completed
OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
Gender:
ALL
Ages:
All
Trial Updated:
09/08/2008
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
Register for Updates
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
NCT00016458
Completed
OBJECTIVES: I. Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte globulin in patients with diffuse systemic sclerosis. II. Determine the efficacy of this regimen in terms of controlling disease in these patients.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
09/02/2008
Locations: University of Colorado Cancer Center, Denver, Colorado +2 locations
Conditions: Systemic Sclerosis
Register for Updates
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
NCT00705120
Completed
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III. Compatible sibling donors and unrelated donors were stratified and analyzed according to the type of donor. All patients with a sibling donor will received a chemotherapy conditioning regimen; a non-T cell depleted allogeneic marrow, and GVHD prophylaxis. All patients with an unrelated donor will receive a chemoradiotherapy conditioni... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
06/23/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Osteogenesis Imperfecta
Register for Updates
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL
NCT00187161
Completed
This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/03/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Mature B-Cell
Register for Updates
Large Cell Lymphoma Pilot Study III
NCT00187070
Completed
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/06/2008
Locations: St. Jude Children's Reaearch Hospital, Memphis, Tennessee
Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Register for Updates
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
NCT00667927
Completed
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/25/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Myeloid Leukemia
Register for Updates
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
NCT00187122
Completed
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
Gender:
ALL
Ages:
All
Trial Updated:
04/21/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Lymphoblastic Lymphoma
Register for Updates
Drug Therapy in Lupus Nephropathy
NCT00001212
Completed
Studies have shown that up to 26% of patients with systemic lupus erythematoses nephritis may suffer from membranous lupus nephropathy. The disease is characterized by high levels of protein in the urine and may eventually lead to kidney failure. This study will evaluate the effectiveness and toxic effects of immunosuppressive drug therapy in patients with membranous lupus nephropathy over a 12 month period. The major goal of this therapy is to decrease protein losses and ultimately prevent kid... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/08/2008
Locations: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland
Conditions: Nephrotic Syndrome, Systemic Lupus Erythematosus
Register for Updates
Treatment of Wegener's Granulomatosis With Cyclophosphamide
NCT00001155
Completed
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland
Conditions: Vasculitis, Wegener's Granulomatosis
Register for Updates